默沙东新冠特效药在哪买？

Where to buy Merck’s new coronavirus drug

Merck's new coronavirus specific drug Monupivir/Monapiravir can be purchased in domestic hospital pharmacies, and is also called Monopiravir in China. Merck's new coronavirus specific drug can be used for infectious diseases (new coronavirus infection) caused by SARS-CoV-2. It will be launched in China on December 30, 2022, and in the United States on December 23, 2021, which means it can be purchased at home and abroad.

It is currently known that the price of Merck's new coronavirus specific drug Monupivir/Monoravir in the domestic market is about US$700 per course of treatment, which is approximately RMB 4,700. The specification is 200mg per pill; 40 pills per bottle. The current reference price of Monupivir/Monoravir in the overseas market is about 350 per box, and the specifications are 200 mg per pill; 40 pills per bottle. Due to the impact of exchange rate fluctuations, overseas drug prices are not fixed. For more details about the price of Monupivir/Monoravir, please consult customer service staff.

How to take Merck’s new coronavirus specific drug

Merck's new coronavirus specific drug Monupivir/Monoravir can be taken before or after meals. Usually, patients over 18 years old take oral monopivir/monoravir, 800 mg (4 pills) each time, 2 times a day (8 pills), for 5 days. In other words, one bottle of medicine is just enough for a 5-day course of treatment. Merck's COVID-19 specific drug Monupivir/Monoravir is a hard capsule. The contents are white to light yellow particles. Swallow them whole with water. Do not open, crush or chew them. It is recommended that patients take medication under the guidance of a doctor and receive symptomatic treatment.

Merck's new coronavirus specific drug Monupivir/Monoravir is an RNA polymerase inhibitor that can bind to the RNA polymerase of the new coronavirus and introduce incorrect nucleotides into newly synthesized RNA molecules, thereby inhibiting or eliminating the virus. Merck's COVID-19 specific drug Monupivir/Monoravir has obtained marketing approval or emergency use authorization in more than 20 countries or regions around the world, including the United States, the European Union, the United Kingdom, Australia, Japan, South Korea, etc.

Recommended related articles: